Boehringer Ingelheim Reports Results of Ofev (nintedanib) in INMARK Study for Patients with Idiopathic Pulmonary Fibrosis (IPF)

 Boehringer Ingelheim Reports Results of Ofev (nintedanib) in INMARK Study for Patients with Idiopathic Pulmonary Fibrosis (IPF)

Boehringer Ingelheim Signs a Clinical Research Agreement with Amal for the Evaluation of Combination Therapy to Treat Stage IV Colorectal Cancer

Shots:

  • The INMARK study involves assessing of Ofev (nintedanib) vs PBO in 347 patients with IPF for 12 wks., followed by an open label period of 40 wks.
  • The study resulted @12 wks lower rate of FVC decline (18.5 vs 13.1), with no rate of change in CRPM, 29% of the subjects experienced FVC decline of ≥10%  
  • Ofev is a tyrosine kinase inhibitor, shown to slow disease progression by reducing lung function decline and was also included in updated international treatment guidelines for IPF in 2017, approved in 70+ countries including the US, EU and Japan for IPF

Click here to read full press release/ article | Ref: Boehringer Ingelheim | Image: Australia247

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post